Skip to content
value.today
Corvus Pharmaceuticals, Inc. logo

Corvus Pharmaceuticals, Inc.

Total raised
$88 M
2 rounds on record
Latest round
$75 M
Sep 2015
First round on record
Nov 2014
Today
Went public
See the company page

Corvus Pharmaceuticals, Inc. is listed today as Corvus Pharmaceuticals, Inc.: market value, financials and filings are on its company page.

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Corvus Pharmaceuticals, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Sep 2015$75 MNo. 2$50 to $250 million

Corvus Pharmaceuticals, Inc.: Raise no. 2, Sep 2015

Investors in this round

33 investors had bought by the notice of Sep 25, 2015: 33 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 3 investors are named for Corvus Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$75 M of $75 M offered
Smallest investment taken
no minimum stated
What was sold
equity, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Leiv P. Lea · Executive Officer
  • Richard A. Miller · Executive Officer, Director
  • Elisha (Terry) P. Gould · Director
  • Peter P. Moldt · Director
  • Peter P. Thompson · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Alan C. Mendelson, Secretary. Source: SEC Form D, newest notice filed Sep 25, 2015. Read the notice at the SEC.

equitySEC
Nov 2014$13 MNo. 1$10 to $50 million

Corvus Pharmaceuticals, Inc.: Raise no. 1, Nov 2014

Investors in this round

12 investors had bought by the notice of Dec 8, 2014: 12 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 3 investors are named for Corvus Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$13 M of $34 M offered; $21 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Leiv G. Lea · Executive Officer
  • Richard A. Miller · Executive Officer, Director
  • Peter G. Thompson · Director
  • Terry G. Gould · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Alan C. Mendelson, Secretary. Source: SEC Form D, newest notice filed Dec 8, 2014. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Corvus Pharmaceuticals, Inc. chose not to state its revenue in its newest notice of a funding round (Sep 2015).

    SEC Form D · Sep 2015

  • The industry group it chose in its notices: Other Health Care.

    SEC Form D · Sep 2015

That is all the official record says: Corvus Pharmaceuticals, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of Corvus Pharmaceuticals, Inc. are on record.

Investors#

3 named in official filings. Open an investor to see everything it has backed.

Investors in Corvus Pharmaceuticals, Inc.
InvestorKindAmountRoundRoleSource
Adams Street Partners LLCFund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2016)SEC Form 3
Novo Holdings A/sFund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2016)SEC Form 3
Orbimed Advisors LLCFund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner, director (Form 3, 2016)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 33 investors.

Largest shareholders today

Institutions holding Corvus Pharmaceuticals, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Corvus Pharmaceuticals, Inc.
NameRoleNamed in
Leiv P. LeaExecutive officerSep 2015
Richard A. MillerExecutive officerSep 2015
Leiv G. LeaExecutive officerDec 2014
Elisha (Terry) P. GouldDirectorSep 2015
Peter P. MoldtDirectorSep 2015
Peter P. ThompsonDirectorSep 2015
Richard A. MillerDirectorSep 2015
Peter G. ThompsonDirectorDec 2014
Terry G. GouldDirectorDec 2014

Went public since 2016. Its SEC number is that of a company listed on a stock exchange.